ghk-cu hair growth clinical trial human GHK Peptide (2016) — Research Summary ghk-cu hair growth clinical trial

Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype

While the mechanistic data for how LDN and these specific peptides work is strong and growing, large-scale, double-blind clinical trials for their combined use in Hashimotos are still lacking

Want to see what others are saying

I had no complication whatsoever

Sikiric's lab in Croatia) No independent replication No competing research Raises red flags about bias Human data: ONE small retrospective study (not a randomized trial) No large-scale clinical trials No safety studies Unknown dosing Unknown side effects Recent systematic review (2024): Published in orthopaedic literature, concluded: "BPC-157 has potential based on preclinical data, but there is a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without publication." Reported Side Effects (From Online Users): Anonymous reports include: Injection site pain and swelling Joint pain Anxiety and panic attacks Heart palpitations Insomnia or drowsiness Fatigue and weakness Loss of appetite Depression and anhedonia (inability to feel pleasure) Note: These are anecdotal, not from clinical trials